NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Enliven Therapeutics, Inc. ELVN
7 fiscal years on record · USD · FY2025 reported · SEC filings only
$-103.7M
$-70.5M
Growth
—
Revenue, FY2025 · full 7-year series below
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
—
ROE
FY2025 · ROE -27.0%
Each USD of equity lost 27 cents this year.
The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue $B | · | · | · | · | · | · | · |
| Operating income $B | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| EBITDA $B | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | · | · | · |
| Net income $B | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 | −0.0 | −0.0 |
| Free cash flow $B | −0.1 | −0.1 | −0.1 | −0.0 | −0.0 | −0.0 | −0.0 |
| EPS, diluted $ | −1.83 | −1.89 | −2.01 | −12.05 | −2.37 | −3.53 | −33.40 |
| Dividend / sh $ | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · |
| ROE % | −27.0 | −32.0 | −84.7 | · | −247.3 | −232.4 | · |
| Shares out B | 0.06 | 0.05 | 0.04 | 0.00 | 0.03 | 0.02 | 0.00 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 1 failures in 28 reconciliationsAUDITED
Reconciled in 6 of 19 fiscal years. 48 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente1 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2019